TrialBlood advances2024
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5106.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.